GE HealthCare Technologies Inc. (GEHC) Covered Calls
GE HealthCare Technologies Inc. is a leading global medical technology and digital solutions innovator. Spun off from GE in 2023, the company operates through four segments: Imaging, Patient Care Solutions, Pharmaceutical Diagnostics, and Advanced Visualization. It provides advanced medical imaging, ultrasound, patient monitoring, and contrast media used in diagnosis and therapy. The firm leverages artificial intelligence to drive better patient outcomes and clinical efficiency.
You can sell covered calls on GE HealthCare Technologies Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GEHC (prices last updated Mon 4:16 PM ET):
| GE HealthCare Technologies Inc. (GEHC) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 75.63 | +1.36 | 74.71 | 76.11 | 2.6M | 16 | 34 |
| Covered Calls For GE HealthCare Technologies Inc. (GEHC) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 76 | 1.50 | 74.61 | 1.9% | 57.8% | |
| Apr 17 | 75 | 3.50 | 72.61 | 3.3% | 30.1% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
GE HealthCare Technologies Inc. (GEHC) is a premier global medical technology innovator, serving as a critical pillar of the modern healthcare system. Following its successful transition to a pure-play healthcare company, it has focused on "precision care"—the integration of smart devices, digital apps, and pharmaceutical diagnostics to improve the efficiency and accuracy of patient screening, diagnosis, and treatment monitoring on a global scale.
Core Business and Products
- Imaging: This is the company’s largest segment, providing essential diagnostic equipment including computed tomography (CT), magnetic resonance (MRI), molecular imaging (PET/SPECT), and X-ray systems. In 2026, the company expanded this portfolio with the "Allia Moveo" platform, an AI-guided mobile C-arm designed for complex interventional procedures.
- Ultrasound: A global leader in ultrasound technology, the company offers specialized systems for radiology, cardiology, and women’s health. Its "Voluson" line remains a benchmark in maternal-fetal medicine, recently enhanced through AI-enabled collaborations with Diagnoly for real-time fetal heart and brain analysis.
- Patient Care Solutions: This division provides monitoring, anesthesia, and respiratory care systems. Strategic innovation includes a 2026 partnership with NXP Semiconductors to deploy "Edge AI" in acute care, enabling hands-free, voice-command interaction with anesthesia equipment and intelligent neonatal monitoring.
- Pharmaceutical Diagnostics: The company is a leading provider of contrast media and radiopharmaceuticals, which are injected into patients to enhance medical imaging. This segment is currently a high-growth driver, fueled by the global demand for molecular imaging and cancer screening.
Competitive Landscape
The medical technology sector is an innovation-led oligopoly. GE HealthCare’s most direct global rivals are Siemens Healthineers and Philips, with whom it shares the majority of the medical imaging market. In the surgical and monitoring space, it competes with Medtronic and Stryker. For diagnostic tools and consumables, it faces competition from Abbott Laboratories and Danaher. Additionally, as the company scales its digital and AI platforms, it increasingly faces pressure from specialized tech firms like Block for healthcare-adjacent payments and business management, and Google in the arena of health-data analytics.
Strategic Outlook and Innovation
In 2026, the company is executing its "Heartbeat" business system, a disciplined operational framework aimed at reducing backlogs and expanding margins toward 16%. A cornerstone of its strategy is the "Vivid Pioneer" cardiovascular ultrasound system, which leverages NVIDIA’s accelerated computing to process up to 50 times more data than traditional systems. Management is prioritizing a "vitality rate" strategy, ensuring that over 50% of annual revenue is derived from products launched within the last three years. Innovation is centered on "Agentic AI" through the AI Innovation Lab, which develops autonomous interpretation tools for mammography and cancer recurrence prediction. With over 70 FDA-authorized AI devices, the company is positioning itself as the "operating system" for hospitals, shifting from hardware sales to recurring revenue through software-as-a-service (SaaS) and multi-year enterprise agreements. The long-term goal remains focused on delivering 3-4% organic revenue growth while maintaining a fortress balance sheet for strategic acquisitions in the digital health space.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | KSS covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | OWL covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | USO covered calls | |
Want more examples? GEF Covered Calls | GEL Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
